ARS Pharmaceuticals Appoints Eric Karas as Chief Commercial Officer and Kathleen Scott as Chief Financial Officer

Appointments Further Strengthen Leadership Team to Support Launch Preparations for neffy™ (epinephrine nasal spray) SAN DIEGO - April 05, 2022 - ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive...

New Data From NeffyTM (ARS-1) Studies Profiled by AAAAI

According to data ARS Pharmaceuticals originally planned to present at the 2020 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) before its cancellation due to the situation with coronavirus disease 2019 (COVID-19), Neffy 1 mg has the potential to be the first intranasal epinephrine spray product...

ARS Pharmaceuticals Announces the Appointment of Two New Board Members

Expansion of Board of Directors Adds Commercialization and Financial Expertise,  Further Augments Clinical and Scientific Acumen of Medical and Scientific Advisory Board  SAN DIEGO – June 18, 2019 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions...